This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Navidea Biopharmaceuticals Inc (NAVB)

AMEX: Health Care

Company Cash Flow
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Cash Flow From Operating Activities
Net Income (Loss) -42.70M -29.16M 5.61M -49.96M
Operating Gains/Losses 1.37M 1.15M -26.16M 41.72M
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables -1.04M 6.50K -219.02K -707.91K
(Increase) Decrease in Inventories -1.93M 524.05K -53.29K -381.38K
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00 0.00
(Decrease) Increase In Payables 1.00M 736.11K -538.67K 759.41K
(Decrease) Increase In Other Current Liabilities 3.18M 125.14K 487.06K 0.00
(Increase) Decrease In Other Working Capital 0.00 0.00 109.50K 390.76K
Other Non-Cash Items 3.26M 2.33M 4.61M 2.75M
Net Cash From Continuing Operations -35.61M -23.92M -16.01M -5.17M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities -35.61M -23.92M -16.01M -5.17M
Sale of Property, Plant & Equipment 0.00 0.00 1.00K 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 0.00 0.00 0.00 0.00
Purchases of Property, Plant & Equipment -1.29M -671.81K -236.33K -398.74K
Acquisitions 0.00 0.00 30.16M 0.00
Purchases of Short-Term Investments 0.00 0.00 0.00 0.00
Other Cash from Investing Activities 0.00 0.00 -2.77M 0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities -1.29M -671.81K 27.16M -398.74K
Issuance of Debt 29.00M 4.00M 7.00M 0.00
Cash Used for Financing Activities
Issuance of Capital Stock 41.30M 0.00 7.20M 7.09M
Repayment of Long-Term Debt -5.99M -1.29M -71.03K -20.34K
Repurchase of Capital Stock 0.00 -100.88K 0.00 -611.26K
Payment of Cash Dividends 0.00 -100.00K -100.00K -111.39K
Other Financing Charges, Net -3.59M 2.56M -2.95M 0.00
Net Cash From Financing Activities 60.72M 5.07M 11.08M 6.35M
Effect of Exchange Rate Changes 0.00 0.00 0.00 0.00
Net Change in Cash & Cash Equivalents 23.82M -19.53M 22.22M 780.66K
NAVB News

NAVB Navidea Biopharmaceuticals Inc

Analysts Ratings for NAVB

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 1 1 1 1
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET NAVB ANALYST REPORT

Brokerage Partners

NAVB Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs